ND0 59
Alternative Names: ND0-59Latest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator Numab
- Developer Boehringer Ingelheim; Numab
- Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry macular degeneration
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Dry macular degeneration in Germany (Parenteral)
- 08 Jul 2020 Boehringer Ingelheim and Numab Therapeutics enters into a research collaboration and worldwide licensing agreement
- 08 Jul 2020 Early research in Dry macular degeneration in Switzerland (Parenteral), Germany (Parenteral)